This facilitates shared decision making by patients and oncologists to select treatments that are high value.10 Since their validation, more analyses have been done using these methods in variety of cancer types and treatment settings including both curative and palliative scenarios.11-13 Currently, there is little known about the risk-benefit ratio informed by the ASCO value framework and ESMO value framework for anti-PD-1 and anti-PD-L1 therapies among all published randomized trials for esophageal and gastric cancer. This evidence concerns the gene CD274 and cancer.